Patent · US Expired

Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor

US6166288A · kind A · utility

62Cited by
2References
40Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 3, 1996
Grant dateDec 26, 2000
Priority date
Expiry dateJul 3, 2016

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K48/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method of xenotransplanting organs, tissues, cells or non-viable components which reduces or prevents antibody-mediated rejections, including hyperacute rejection, is provided wherein transgenic animals are produced that express at least one enzyme which masks or reduces the level of the antigenic Gal.alpha.(1,3)Gal or gal epitope, and at least one complement inhibitor such as CD59, DAF and/or MCP. The transgenic animals which express both a gal epitope-reducing enzyme and a complement inhibitor will have masked or reduced levels of the gal epitope and will be much less likely to produce an antibody-mediated rejection following transplantation, and the expression of the complement inhibitor will also suppress complement activation and reduce even further a severe immune reaction following the transplantation of donor organs, tissue, cells or non-viable components from the transgenic animals so produced. In addition, transgenic animals are provided which express a plurality of complement inhibitors or other proteins from a locus of genes at a single integration site. The present invention is thus advantageous in that it can provide xenogeneic organs, tissues, cells and non-viable …

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.